Compugen to Screen Peptides for Pfizer | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen said today that it will screen peptide candidates for three Pfizer drug targets.

Under the collaboration, Compugen will use its predictive models, algorithms, and computational biology methods to discover and synthesize molecules for the drug maker. Pfizer will pay Compugen for the research, and it will have the right to options for worldwide and exclusive milestones and licenses to develop and commercialize the selected candidates, Compugen said.

Compugen said it expects the studies to take a few months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.